PTO/SB/084 (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to e collection of information unless it contains a valid OMB control number Complete if Known

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)

of 1

Substitute for form 1449/PTO

Sheet 1

Application Number To be assigned Filing Date April 26, 2006 First Named Inventor BRIOSCHI, Roberto Art Unit To be assigned Examiner Name To be assigned Attorney Docket Number 16879US

U. S. PATENT DOCUMENTS									
Examiner Initials*	No.1	Document Number  Number-Kind Code <sup>2 of Amount</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, When Relevant Passeges or Relever Figures Appear				
	A1	<sup>US-</sup> 1,837,129 A	12-27-1931	J. B. Maples					
		us-							
		US-							
		US-							
		US-							
		US-	1						
		US-							
		US-							
		US-							
		U\$-							
		US-							
		US-	1						
		US-							
		US-							
		US-							
		US-	1						
		US-							
		U8-							
		US-							

			IGN PATENT DOCU			
Examiner Initiels*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pessages Or Relevant Figures Appear	70
		Country Code <sup>2</sup> Number <sup>4*</sup> Kind Code <sup>3</sup> (#Anown)	MM-DD-YYYY			
	81	FR 2 660 957 A	10-18-1991	Daniel Marcellini et al.		
	82	DE 8 807 C	06-20-1879	A. Luckau Jr.		
	B3	DE 44 28 983 A	02-22-1996	Erich Ruth		
	84	WO 91/14070 A	09-19-1991	Havaco Folientechnik		

Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered, brinder copy of this form with east communication to applicant a verigine challent designation number (optional). "See Yorks Code or USPTO Period Consomers at items requiring on WRPP 9011A." Extent Clinic leaf is assessed the document, by the two-belies code WRPD Standards 573, "For Superiors patent document, the indication of the year of the region of the Experior must precede the sental number of the potent document. "Nittle of document the appropriate options are indicated in the properties option as indicated in the document under WRPD Standards 1714 is prossible." "Applicant is to price or check mark tree of English language." Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is rec ired to obtain or retain a benefit by the public which is to file (and by the This Collection of intermediate in explaned by 37 CPM 137 and 135. The selection of intermediate is explaned to Globest on internal both and to State of the Collection in estimated to black 2 but no complete. UNEFFO by processing an explanation. Confidentially in government by all ULE. 122 and 27 CPM 14. This collection is estimated to black 2 bound to complete, processing the collection of the Collecti

TO: Commissioner for Patants, P.O. Box 1460, Alexandris, VA 22913-1450.

If you need assistance in completing the form. cell 1-800-PTO-9199 (1-800-785-9199) and select option 2

## Privacy Act Statement

The Privacy Act of 1974 (PL. 93-579) requires that you be given certain information in connection with your submission of the attached town related to a patient application or patient Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of the information as 55 U.S. C. 20/(J.C.) (2) missing of the information collected is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademark Office is up process ander examine your submission related to a patient application or patient (1) you do not furnish the requested information, the U.S. Patient and Trademark Office may not be able to only the patient of the patient of the patient produced the p

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of information Act (5 u.S. C. 552) and the Privacy Act (5 u.S. C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of information Act.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing coursel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended nursuant to \$1.5 \text{ SSSSAM}.
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Eneroy Act (42 U.S.C. 218(b)).
- 7. A record from this system of records may be disclosed, as a routine use, be the Administrator, General Services or higher designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under submiyer of 44 U.S. C. 2054 and 2050. South disclosure shall practice and programs, under submiyer of 44 U.S. C. 2054 and 2050. South disclosures when the contraction of the contracti
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(3)) or issuance of a patient pursuant to 35 U.S. C. 15(1). Further, a record may be disclosed, subject to the limitations of 37 CFR. 1.1.4, as a routine use, to the public if the record uself float in anyplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public impetion or an extension of the public impetion or an extension of the publication of the public impetion or an extension of the public impetion or an extension of the public in the publication of the public impetion or an extension of the publication of the publica
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or reculation.